Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain

The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in recent years.However,several barriers to imple...

Descripción completa

Detalles Bibliográficos
Autores: García-Agúndez, José Augusto, Abad Santos, Francisco, Aldea, Ana, Alonso-Navarro, Hortensia, Bernal, María Luisa, Borobia Pérez, Alberto M., Borràs, Emma, Carballo, Miguel, Carvajal, Alfonso, García-Muñiz, José D., Gervasini, Guillermo, Jiménez-Jiménez, Félix Javier, Lucena, María Isabel, Martínez, Carmen, Sacristán, José A., Salado, Inés, Sinués, Blanca, Vicente, Jorge, García-Martín, Elena
Tipo de recurso: artículo
Fecha de publicación:2012
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/668838
Acceso en línea:http://hdl.handle.net/10486/668838
https://dx.doi.org/10.3389/fgene.2012.00273
Access Level:acceso abierto
Palabra clave:Adverse drug reactions
Biomarkers
Clinical recommendations
Clinical relevance
Pharmacogenomics
Farmacia
Descripción
Sumario:The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in recent years.However,several barriers to implementing the use of pharmacogenomics testing exist.We conducted a survey among members of the Spanish Societies of Pharmacology and Clinical Pharmacology to obtain information about the perception of such barriers and to compare the perceptions of participants about the relative importance of majorgene/drug pairs.Of 11 potential barriers,the highest importance was attributed to lack of institutional support for pharmacogenomic stesting,and to the issues related to the lack of guidelines.Of the proposed gene/drug pairs the highest importance was assigned to HLA-B/abacavir, UGT1A1/irinotecan, and CYP2D6/tamoxifen.In this perspective article,we compare the relative importance of 29 gene/drugpairs in the Spanish study with that of the same pairs in the American Society for Clinical Pharmacology and Therapeutic sstudy,and we provide suggestions and areas of focus to develop a guide for clinical practice in pharmacogenomics testing

Similares en LA Referencia